This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Liver Transplantation and Uveal Malignant Melanoma

This study has been completed.
Information provided by (Responsible Party):
Svein Dueland, Oslo University Hospital Identifier:
First received: March 7, 2011
Last updated: March 30, 2016
Last verified: March 2016
Patients with uveal malignatnt melanoma with liver metastases have a dismal prognosis with a median survival of less than 12 months. There is noe established treatment showing increased overall survival. In this study we will determin if liver transplantation will result in long term survival in patients with liver only metastases from uveal malignant melanoma.

Condition Intervention Phase
Uveal Malignant Melanoma Procedure: Liver transplantation Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Svein Dueland, Oslo University Hospital:

Primary Outcome Measures:
  • Over all survival

Enrollment: 2
Study Start Date: January 2011
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Liver transplantation Procedure: Liver transplantation


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:Uveal malignant melanoma, liver only metastases, ECOG 0-1 -

Exclusion Criteria:Extra hepatic disease, previous other maligency, previous organ transplantation

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01311466

Oslo University Hospital
Oslo, Norway, N0310
Sponsors and Collaborators
Oslo University Hospital
  More Information

Responsible Party: Svein Dueland, MD PhD, Oslo University Hospital Identifier: NCT01311466     History of Changes
Other Study ID Numbers: S-06408
Study First Received: March 7, 2011
Last Updated: March 30, 2016

Keywords provided by Svein Dueland, Oslo University Hospital:
Liver transplantation
Overall survival

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Liver Extracts
Hematinics processed this record on September 21, 2017